Serum neopterin in chronic beryllium disease

Area of Science:

• Occupational Health
• Biomarker Discovery
• Immunology

Background:

• Chronic beryllium disease (CBD) is a serious occupational lung disease.
• Current screening involves the beryllium lymphocyte proliferation test (BeLPT), which can have limitations.
• Need for reliable biomarkers to aid in CBD diagnosis and screening.

Purpose of the Study:

• To evaluate serum neopterin as a biomarker for chronic beryllium disease (CBD).
• To assess the utility of serum neopterin in conjunction with the beryllium lymphocyte proliferation test (BeLPT) for workplace screening.
• To determine the diagnostic accuracy of serum neopterin for differentiating CBD from beryllium sensitization (BeS).

Main Methods:

• Serum neopterin levels were measured using radioimmunoassay in three groups: CBD (n=86), beryllium sensitized (BeS) (n=22), and normal (Nor) (n=20).
• Clinical parameters of disease severity, including pulmonary function tests and bronchoalveolar lavage (BAL), were assessed in CBD patients.
• Receiver operator characteristic (ROC) curves were used to determine optimal sensitivity, specificity, and cut-off values for neopterin.

Main Results:

• Median serum neopterin levels were significantly higher in CBD patients compared to BeS and normal groups (P < 0.05).
• Serum neopterin showed significant associations with gas exchange measures and BAL cellularity in CBD patients.
• A neopterin cut-off of 1.27 ng/ml yielded 88% specificity, and serum neopterin demonstrated a 92% positive predictive value in workers with an abnormal BeLPT.

Conclusions:

• Serum neopterin is a promising biomarker for identifying chronic beryllium disease (CBD).
• It can effectively differentiate CBD from beryllium sensitization (BeS), complementing the BeLPT in workplace screening.
• Utilizing serum neopterin may reduce the need for invasive procedures like biopsy.